Srinivasamurthy Banushree Chandrasekhar, Ramamoorthi Subhashini
Department of Pathology, Indira Gandhi Medical College and Research Institute, Puducherry, India.
Department of Pathology, JIPMER, Puducherry, India.
Gynecol Minim Invasive Ther. 2024 Jul 18;13(3):141-145. doi: 10.4103/gmit.gmit_13_23. eCollection 2024 Jul-Sep.
Ovarian cancer is one of the most common cancers with a high mortality rate among females worldwide. The understanding of the pathogenesis of the disease is highly important to provide personalized therapy to the patients. Ovarian cancer is as heterogeneous as colon and breast cancer which makes it difficult to treat. The development of gene signature is the only hope in providing targeted therapy to improve the survival of ovarian cancer patients. Malignant epithelial carcinomas are the most common cancers of the ovary with different histological and molecular subtypes and clinical behavior. The development of precursor lesions of ovarian carcinoma in the tubes and endometrium has provided a new dimension to the origin of ovarian cancers. The clinical utility of various gene signatures may not be logical unless validated. Validated gene signatures can aid the clinician in deciding the appropriate line of treatment.
卵巢癌是全球女性中最常见且死亡率很高的癌症之一。了解该疾病的发病机制对于为患者提供个性化治疗至关重要。卵巢癌与结肠癌和乳腺癌一样具有异质性，这使得其难以治疗。基因特征的发展是提供靶向治疗以提高卵巢癌患者生存率的唯一希望。恶性上皮性癌是卵巢最常见的癌症，具有不同的组织学和分子亚型以及临床行为。输卵管和子宫内膜中卵巢癌前体病变的发展为卵巢癌的起源提供了新的视角。除非经过验证，否则各种基因特征的临床效用可能不合理。经过验证的基因特征可以帮助临床医生确定合适的治疗方案。
